Priority review KTE-X19 for R/R mantle cell lymphoma

May 2020 Pharma News Marjolein Groot
IV set fluid intravenous drop saline drip hospital room,Medical Concept,treatment emergency and injection drug infusion care chemotherapy, light background,selective focus stock photo

Mantle cell lymphoma is a form of lymphatic cancer and a non-Hodgkin lymphoma. Mantle cell lymphoma patients that are refractory or relapsing and show progression of their illness after receiving Bruton’s tyrosine kinase (BTK)-inhibitor therapy, often have a dismal prognosis. For these patients, treatment with KTE-X19, that is currently under investigation, could provide a solution. KTE-X19 is an autologous anti-CD19 chimeric antigen receptor (CAR)-T therapy.


Treatment with KTE-X19 was investigated in the multicentre, phase 2-ZUMA-trial including 74 patients with refractory/relapsing (R/R) mantle cell lymphoma. These patients were R/R after receiving a minimum of 5 therapies, including cBTK-inhibitor therapy.

After going through leukapheresis and bridging therapy if needed, the patients receiving conditioning chemotherapy and a single infusion of KTE-X19 (2*106 CAR-T cells per kg body weights). From the patients that were included, 68 received KTE-X19. The first 60 patients of this group were analysed.

Major response

From the patients that were analysed 93% (95% CI: 84-98) showed an objective response and 67% (95% CI: 53-78%) a complete response. At the time of follow up, 12.3 months on average after treatment (within 7-32.3 month) 57% of the 60 patients were in remission. After a year, the progression-free survival (PFS) was 61% and overall survival (OS) was 83%.

In 94% of patients, cytopenia occurred (stage 3/4) and in 32% an infection (stage 3/4). Moreover, 15% of patients experienced cytokine release syndrome (grade 3/4) and 31% of patients a neurological event. Two patients passed away due to infectious adverse events.

Priority review

The FDA accepted the Biologics Licence Applications of KTE-X19 and assigned priority review to the pharmaceutical. This entails that the FDA expects that KTE-X19 will provide a significant improvement in safety or efficacy of the treatment of R/R mantle cell lymphoma. The EMA has also recently given out marketing authorisation for KTE-X19 in the EU. Registration is expected in December 2020.


  1. Wang M, Munoz J, Goy A, et al. (2020). KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma. New England Journal of Medicine382(14), 1331-1342.